PharmaVentures has been engaged to act as an advisor to Volition to help secure licensing deals with industry leaders for both Nu.Q® Cancer – a range of simple blood-based assays to help detect, guide treatment, and monitor cancer, and Capture-PCR™ – a novel detection method for liquid biopsy in cancer and potentially other diseases. Adrian Dawkes, Managing Director, PharmaVentures, said: Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving li ...

VolitionRx Limited (NYSE:VNRX) Q1 2024 Results Conference Call May 14, 2024 8:30 AM ET Company Participants Cameron Reynolds - President, CEO Terig Hughes - CFO Andrew Retter - CMO Gael Forterre - CCO Louise Batchelor - Chief Marketing & Communications Officer Conference Call Participants Bruce Jackson - Benchmark Company Tim Moore - EF Hutton Ilya Zubkov - Freedom Broker Steven Ralston - Zacks Richard Deutsch - Sutter Securities Operator Good morning, ladies and gentlemen, and thank you for standing by. We ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36833 VolitionRx Limited (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization ...

FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 13, 2024 VolitionRx Limited (Exact name of registrant as specified in its charter) | Delaware | 001-36833 | 91-1949078 | | --- | --- | --- | | (State or other jurisdiction | (Commission | (IRS Employer | | of Incorporation) | File Number) | Identification Number) | 1489 West Warm Springs Road, Suite 110 Henderson, Nevada 89014 (Address of Principal Executive Of ...

VolitionRx Limited (NYSE:VNRX) Q4 2023 Results Conference Call March 26, 2024 8:30 AM ET Company Participants Louise Batchelor - Chief Marketing and Communications Officer Cameron Reynolds - President and Group Chief Executive Officer Terig Hughes - Group Chief Financial Officer Tom Butera - Chief Executive Officer, Volition Veterinary Subsidiary Andrew Retter - Medical Consultant, Volition Conference Call Participants Tim Moore - EF Ilya Zubkov - Freedom Broker Bruce Jackson - The Benchmark Company Steven ...

FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to (I.R.S. Employer Identification No.) 1489 West Warm Springs Road, Suite 110 Henderson, Nevada 89014 (Address of principal executive offices) +1 (646) 650–1351 (Registrant's t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 25, 2024 VolitionRx Limited (Exact name of registrant as specified in its charter) (Registrant's telephone number, including area code ) Not applicable (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simu ...

VolitionRx Limited (NYSE:VNRX) Q3 2023 Earnings Conference Call November 15, 2023 8:30 AM ET Company Participants Scott Powell - Executive Vice President, Investor Relations Cameron Reynolds - President and Group Chief Executive Officer Terig Hughes - Group Chief Financial Officer Tom Butera - Chief Executive Officer, Volition Veterinary Subsidiary Andrew Retter - Medical Consultant, Volition Louise Batchelor - Chief Marketing and Communications Officer Conference Call Participants Ross Osborn - Cantor Fitz ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36833 VOLITIONRX LIMITED (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organiza ...

VolitionRx Limited (NYSE:VNRX) Q2 2023 Results Conference Call August 15, 2023 8:30 AM ET Company Participants Scott Powell - Executive Vice President of Investor Relations Cameron Reynolds - Founder, CEO, President and Director Terig Hughes - CFO & Treasurer Tom Butera - CEO, Volition Veterinary Diagnostics Development LLC Conference Call Participants Bruce Jackson - Benchmark Company Steven Ralston - Zacks Operator Good morning, ladies and gentlemen. Thank you for standing by. Welcome to VolitionRx Limite ...